| Identification | Back Directory | [Name]
Pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-[6-[4-[[(R)-methyloxidophenyl-λ4-sulfanylidene]amino]-1-piperidinyl]-3-pyridinyl]-6-(1-methyl-1H-pyrazol-4-yl)- | [CAS]
2662622-44-6 | [Synonyms]
RET-IN-10
Pyrazolo[1,5-a]pyridine-3-carbonitrile, 4-[6-[4-[[(R)-methyloxidophenyl-λ4-sulfanylidene]amino]-1-piperidinyl]-3-pyridinyl]-6-(1-methyl-1H-pyrazol-4-yl)- | [Molecular Formula]
C29H28N8OS | [MOL File]
2662622-44-6.mol | [Molecular Weight]
536.65 |
| Hazard Information | Back Directory | [Uses]
RET-IN-10 is a potent inhibitor of RET. RET loss of function mutations leads to Hirschsprung's disease, while its gain of function mutations is associated with a variety of human tumors. RET-IN-10 has the potential for the research of cancer diseases (extracted from patent WO2021135938A1, compound 18)[1]. | [References]
[1] Anhu Li. Heterocyclic sulfoximine compounds and intermediates thereof, methods of preparation and applications. Patent WO2021135938A1. |
|
|